Changes of the Types and Daily Costs of Topical Antiglaucoma Medications from 2006 to 2021 in China

IF 2.1 4区 医学 Q3 PHARMACOLOGY & PHARMACY Journal of Clinical Pharmacy and Therapeutics Pub Date : 2023-02-16 DOI:10.1155/2023/7966922
Shuang Zhang, Xuefang Jia, Ying Gao, Lingling Wu
{"title":"Changes of the Types and Daily Costs of Topical Antiglaucoma Medications from 2006 to 2021 in China","authors":"Shuang Zhang, Xuefang Jia, Ying Gao, Lingling Wu","doi":"10.1155/2023/7966922","DOIUrl":null,"url":null,"abstract":"Purpose. To investigate the changes of the types and daily costs of topical antiglaucoma medications from 2006 to 2021 in China, providing evidence for optimizing treatment regimen and medical insurance policy. Methods. The types of topical antiglaucoma drugs except complementary and traditional medicines and associated price information were collected from the largest pharmaceutical database in China (YAOZH database). The daily costs of each drug, the average income level, and the daily cost of topical antiglaucoma medications relative with daily disposable income were calculated and compared between 2006 and 2021. Results. The options of topical antiglaucoma drugs increased remarkably to 32 types in 2021, of which prostaglandin analogs comprised the largest proportion (31.25%). There were 10 types of the same brand drugs available in 2006 and 2021, the mean daily cost of which decreased from $0.39 ± 0.30 to $0.28 ± 0.23 (\n \n p\n <\n 0.001\n \n ). As the average daily disposable income of Chinese residents grew greatly, the proportion of the daily cost of topical antiglaucoma medications in daily disposable income in 2021 declined significantly from 32.52% to 5.78% (all the drugs, \n \n p\n <\n 0.001\n \n ) and 3.94% (without unit dose package, \n \n p\n <\n 0.001\n \n ) in rural areas and from 9.95% to 2.31% (all the drugs, \n \n p\n <\n 0.001\n \n ) and 1.57% (without unit dose package, \n \n p\n <\n 0.001\n \n ) in urban areas. Conclusions. Topical antiglaucoma medications available become much more abundant in China. With the increase of residents’ disposable income and reduction of daily costs of topical antiglaucoma medications, the drug treatment for glaucoma becomes more affordable both in rural and urban areas.","PeriodicalId":15381,"journal":{"name":"Journal of Clinical Pharmacy and Therapeutics","volume":null,"pages":null},"PeriodicalIF":2.1000,"publicationDate":"2023-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Pharmacy and Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1155/2023/7966922","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose. To investigate the changes of the types and daily costs of topical antiglaucoma medications from 2006 to 2021 in China, providing evidence for optimizing treatment regimen and medical insurance policy. Methods. The types of topical antiglaucoma drugs except complementary and traditional medicines and associated price information were collected from the largest pharmaceutical database in China (YAOZH database). The daily costs of each drug, the average income level, and the daily cost of topical antiglaucoma medications relative with daily disposable income were calculated and compared between 2006 and 2021. Results. The options of topical antiglaucoma drugs increased remarkably to 32 types in 2021, of which prostaglandin analogs comprised the largest proportion (31.25%). There were 10 types of the same brand drugs available in 2006 and 2021, the mean daily cost of which decreased from $0.39 ± 0.30 to $0.28 ± 0.23 ( p < 0.001 ). As the average daily disposable income of Chinese residents grew greatly, the proportion of the daily cost of topical antiglaucoma medications in daily disposable income in 2021 declined significantly from 32.52% to 5.78% (all the drugs, p < 0.001 ) and 3.94% (without unit dose package, p < 0.001 ) in rural areas and from 9.95% to 2.31% (all the drugs, p < 0.001 ) and 1.57% (without unit dose package, p < 0.001 ) in urban areas. Conclusions. Topical antiglaucoma medications available become much more abundant in China. With the increase of residents’ disposable income and reduction of daily costs of topical antiglaucoma medications, the drug treatment for glaucoma becomes more affordable both in rural and urban areas.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
2006 - 2021年中国局部抗青光眼药物种类及日常费用的变化
目的。了解2006 - 2021年中国抗青光眼外用药物种类及日常费用的变化情况,为优化治疗方案和医保政策提供依据。方法。除补充药和传统药外,外用抗青光眼药物的种类及相关价格信息收集自中国最大的药品数据库(YAOZH数据库)。计算并比较2006年至2021年各药物的日费用、平均收入水平、外用抗青光眼药物的日费用与日可支配收入的关系。结果。局部抗青光眼药物的选择在2021年显著增加至32种,其中前列腺素类似物所占比例最大(31.25%)。2006年和2021年共有10种同品牌药品可供选择,日均用药费用由0.39±0.30美元降至0.28±0.23美元(p < 0.001)。随着我国居民人均日可支配收入的大幅增长,2021年,外用抗青光眼药物的日费用占居民日可支配收入的比例,农村从32.52%下降到5.78%(全部药品,p < 0.001)和3.94%(无单位剂量包装,p < 0.001),城市从9.95%下降到2.31%(全部药品,p < 0.001)和1.57%(无单位剂量包装,p < 0.001)。结论。在中国,可用的局部抗青光眼药物越来越多。随着居民可支配收入的增加和日常局部抗青光眼药物费用的降低,青光眼的药物治疗在农村和城市都变得更加负担得起。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
4.10
自引率
5.00%
发文量
226
审稿时长
6 months
期刊介绍: The Journal of Clinical Pharmacy and Therapeutics provides a forum for clinicians, pharmacists and pharmacologists to explore and report on issues of common interest. Reports and commentaries on current issues in medical and pharmaceutical practice are encouraged. Papers on evidence-based clinical practice and multidisciplinary collaborative work are particularly welcome. Regular sections in the journal include: editorials, commentaries, reviews (including systematic overviews and meta-analyses), original research and reports, and book reviews. Its scope embraces all aspects of clinical drug development and therapeutics, including: Rational therapeutics Evidence-based practice Safety, cost-effectiveness and clinical efficacy of drugs Drug interactions Clinical impact of drug formulations Pharmacogenetics Personalised, stratified and translational medicine Clinical pharmacokinetics.
期刊最新文献
TH-302: A Highly Selective Hypoxia-Activated Prodrug for Treating PARP Inhibitor–Resistant Cancers Potential Role of APC Mutations in the Prognosis and Targeted Therapy of Gastric Adenocarcinoma The Evaluation for Expandable Applications of Tislelizumab in First-Line Treatment for Advanced Gastric Cancer The Efficacy of Methazolamide Combined With Ibuprofen for Treating Acute Mountain Sickness Protein Kinase Inhibitors Indicated for Lung Cancer: Pharmacodynamics, Pharmacokinetics, Adverse Drug Reactions, and Evaluation in Clinical Trials
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1